Effect of Dotinurad in Hyperuricemia With Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.
Also called NCT06834230
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 360 participants
- Sponsor
- Registry
-
NCT06834230
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Recruiting
Technical summary
Registry record NCT06834230. Randomized; no masking; primary purpose treatment. Start 2025-03-28 (actual); primary completion 2027-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dotinurad in Hyperuricemia With Hypertension
- Acronym
- DIANA-NEXT
- Condition
- Hyperuricemia or Gout
- Condition
- Hypertension
- Intervention (Drug)
- Dotinurad
- Intervention (Drug)
- Febuxostat
- Lead sponsor
- Saga University
Record details
- Record id
cardio:ct-nct06834230- Content hash
f17e78cbcd9815a5ddbf643815b57b697f2af2f510d93f2154323397e234a507